A Phase 1, Randomized, Blinded, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2018
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors MedImmune
- 31 Aug 2018 Biomarkers information updated
- 16 Apr 2018 Status changed from recruiting to completed.
- 28 Feb 2018 Planned End Date changed from 18 May 2018 to 4 May 2018.